Approach for defining human adenovirus infection and disease for central review adjudication in clinical studies
© 2024 The Authors. Pediatric Transplantation published by Wiley Periodicals LLC..
BACKGROUND: Pediatric allogeneic hematopoietic cell transplant (allo-HCT) recipients are at risk for morbidity and mortality from human adenovirus (HAdV). HAdV can be detected in an asymptomatic state, referred to as infection or with signs or symptoms of illness, referred to as disease. Standardized case definitions are needed to distinguish infection from disease and allow for consistent reporting in both observational cohort studies and therapeutic clinical trials.
METHODS: A working group of experts in virology, transplant infectious disease, and HCT was assembled to develop HAdV infection and disease definitions with the degree of certainty (i.e., possible, probable, and proven). Definitions were further refined through an iterative process and independently applied by two central review committees (CRCs) to 20 pediatric allo-HCT recipients with at least one HAdV-positive PCR.
RESULTS: Initial HAdV infection and disease definitions were developed and updated through an iterative process after reviewing clinical and virological details for 81 subjects with at least one positive HAdV PCR detected in a clinical specimen. Independent application of final definitions to 20 HAdV positive allo-HCT recipients by two CRCs yielded similar number of HAdV infection or disease events but with variation of degree of certainty for some events.
CONCLUSIONS: Application of definitions by a CRC for a study of HAdV infection and disease is feasible and can provide consistency in the assignment of outcomes. Definitions need further refinement to improve reproducibility and to provide guidance on determining clinical improvement or worsening after initial diagnosis of HAdV infection or disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Pediatric transplantation - 28(2024), 3 vom: 16. Apr., Seite e14750 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fisher, Brian T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hematopoietic cell transplantation |
|---|
| Anmerkungen: |
Date Completed 17.04.2024 Date Revised 26.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/petr.14750 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371130018 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371130018 | ||
| 003 | DE-627 | ||
| 005 | 20240426234316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/petr.14750 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM371130018 | ||
| 035 | |a (NLM)38623880 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fisher, Brian T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Approach for defining human adenovirus infection and disease for central review adjudication in clinical studies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Pediatric Transplantation published by Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Pediatric allogeneic hematopoietic cell transplant (allo-HCT) recipients are at risk for morbidity and mortality from human adenovirus (HAdV). HAdV can be detected in an asymptomatic state, referred to as infection or with signs or symptoms of illness, referred to as disease. Standardized case definitions are needed to distinguish infection from disease and allow for consistent reporting in both observational cohort studies and therapeutic clinical trials | ||
| 520 | |a METHODS: A working group of experts in virology, transplant infectious disease, and HCT was assembled to develop HAdV infection and disease definitions with the degree of certainty (i.e., possible, probable, and proven). Definitions were further refined through an iterative process and independently applied by two central review committees (CRCs) to 20 pediatric allo-HCT recipients with at least one HAdV-positive PCR | ||
| 520 | |a RESULTS: Initial HAdV infection and disease definitions were developed and updated through an iterative process after reviewing clinical and virological details for 81 subjects with at least one positive HAdV PCR detected in a clinical specimen. Independent application of final definitions to 20 HAdV positive allo-HCT recipients by two CRCs yielded similar number of HAdV infection or disease events but with variation of degree of certainty for some events | ||
| 520 | |a CONCLUSIONS: Application of definitions by a CRC for a study of HAdV infection and disease is feasible and can provide consistency in the assignment of outcomes. Definitions need further refinement to improve reproducibility and to provide guidance on determining clinical improvement or worsening after initial diagnosis of HAdV infection or disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hematopoietic cell transplantation | |
| 650 | 4 | |a human adenovirus | |
| 650 | 4 | |a pediatrics | |
| 700 | 1 | |a Blumenstock, Jesse |e verfasserin |4 aut | |
| 700 | 1 | |a Boge, Craig L K |e verfasserin |4 aut | |
| 700 | 1 | |a Shuster, Sydney |e verfasserin |4 aut | |
| 700 | 1 | |a Seif, Alix E |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Michaels, Marian G |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, Jessie L |e verfasserin |4 aut | |
| 700 | 1 | |a Ardura, Monica I |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Tamara P |e verfasserin |4 aut | |
| 700 | 1 | |a Hijano, Diego R |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, William J |e verfasserin |4 aut | |
| 700 | 1 | |a Schuster, Jennifer E |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Abby M |e verfasserin |4 aut | |
| 700 | 1 | |a Dulek, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Kajon, Adriana E |e verfasserin |4 aut | |
| 700 | 1 | |a Danziger-Isakov, Lara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric transplantation |d 1997 |g 28(2024), 3 vom: 16. Apr., Seite e14750 |w (DE-627)NLM097406473 |x 1399-3046 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:3 |g day:16 |g month:04 |g pages:e14750 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/petr.14750 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 3 |b 16 |c 04 |h e14750 | ||